Commemorative candidate vaccine vials stand on display in the office Stéphane Bancel, the CEO of the pharmaceutical and biotechnology company Moderna, seen here at Moderna's offices in Cambridge, Massachusetts, USA, on Mon., Nov. 14, 2022. Moderna is best-known for its mRNA COVID-19 vaccine, but is working on vaccines for other diseases including a personal cancer vaccine. Employees at the company get these commemorative vials for any vaccines that go to clinical trials while they work at the company.

For French business weekly Le Point, I visited two of Moderna’s lab and office facilities in Massachusetts to photograph inside their labs and the company’s CEO Stéphane Bancel as the company moves beyond the coronavirus vaccine and pushes toward a so-called personalized cancer vaccine. 

It was a difficult shoot with extremely limited access; lab spaces were generally off-limits or behind glass and had about 3 minutes for portraits with the CEO. 

Moderna employees work at desks near a lab in pharmaceutical company Moderna's MTC-North building in Norwood, Massachusetts, USA, on Wed., Nov. 2, 2022.
Stéphane Bancel is the CEO of the pharmaceutical and biotechnology company Moderna, seen here at Moderna's offices in Cambridge, Massachusetts, USA, on Mon., Nov. 14, 2022. Moderna is best-known for its mRNA COVID-19 vaccine, but is working on vaccines for other diseases including a personal cancer vaccine.
Seen in his office during an interview with Le Point reporter François Miguet, Stéphane Bancel is the CEO of the pharmaceutical and biotechnology company Moderna, seen here at Moderna's offices in Cambridge, Massachusetts, USA, on Mon., Nov. 14, 2022. Moderna is best-known for its mRNA COVID-19 vaccine, but is working on vaccines for other diseases including a personal cancer vaccine.
Stéphane Bancel is the CEO of the pharmaceutical and biotechnology company Moderna, seen here at Moderna's offices in Cambridge, Massachusetts, USA, on Mon., Nov. 14, 2022. Moderna is best-known for its mRNA COVID-19 vaccine, but is working on vaccines for other diseases including a personal cancer vaccine.
A scientist works with automated pipetting equipment in Moderna's lab for preclinical research and tech development in pharmaceutical company Moderna MTC-North building in Norwood, Massachusetts, USA, on Wed., Nov. 2, 2022.
Scientists work in Moderna's lab for preclinical research and tech development in pharmaceutical company Moderna MTC-North building in Norwood, Massachusetts, USA, on Wed., Nov. 2, 2022.
A scientist works with automated pipetting equipment in Moderna's lab for preclinical research and tech development in pharmaceutical company Moderna MTC-North building in Norwood, Massachusetts, USA, on Wed., Nov. 2, 2022.
A multi-person glovebox stands in a lab in pharmaceutical company Moderna's MTC-North building in Norwood, Massachusetts, USA, on Wed., Nov. 2, 2022.
A lab in pharmaceutical company Moderna's MTC-North building in Norwood, Massachusetts, USA, on Wed., Nov. 2, 2022.
An exterior view of pharmaceutical company Moderna's manufacturing building in Norwood, Massachusetts, USA, on Wed., Nov. 2, 2022.
All content © 2005-2024 M. Scott Brauer